These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 8781492)

  • 1. Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin.
    Herbert JM; Hérault JP; Bernat A; van Amsterdam RG; Vogel GM; Lormeau JC; Petitou M; Meuleman DG
    Circ Res; 1996 Sep; 79(3):590-600. PubMed ID: 8781492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.
    Herbert JM; Hérault JP; Bernat A; van Amsterdam RG; Lormeau JC; Petitou M; van Boeckel C; Hoffmann P; Meuleman DG
    Blood; 1998 Jun; 91(11):4197-205. PubMed ID: 9596667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SR123781A, a synthetic heparin mimetic.
    Herbert JM; Hérault JP; Bernat A; Savi P; Schaeffer P; Driguez PA; Duchaussoy P; Petitou M
    Thromb Haemost; 2001 May; 85(5):852-60. PubMed ID: 11372679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216.
    Carrie D; Caranobe C; Saivin S; Houin G; Petitou M; Lormeau JC; Van Boeckel C; Meuleman D; Boneu B
    Blood; 1994 Oct; 84(8):2571-7. PubMed ID: 7919374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
    Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide.
    Meuleman DG; Hobbelen PM; Van Dinther TG; Vogel GM; Van Boeckel CA; Moelker HC
    Semin Thromb Hemost; 1991; 17 Suppl 1():112-7. PubMed ID: 2068564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-clinical pharmacological profile of the novel glycoconjugate Org 36764 with both factor Xa and thrombin (IIa) inhibitory activities.
    Vogel GM; van Amsterdam RG; van Dinther TG; Tromp M; Meuleman DG
    Thromb Haemost; 2000 Oct; 84(4):611-20. PubMed ID: 11057859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity.
    Vogel GM; Meuleman DG; Van Dinther TG; Buijsman R; Princen AW; Smit MJ
    J Thromb Haemost; 2003 Sep; 1(9):1945-54. PubMed ID: 12941035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.
    Vogel GM; van Amsterdam RG; Kop WJ; Meuleman DG
    Thromb Haemost; 1993 Jan; 69(1):29-34. PubMed ID: 8446935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
    Herbert JM; Bernat A; Dol F; Hérault JP; Crépon B; Lormeau JC
    J Pharmacol Exp Ther; 1996 Mar; 276(3):1030-8. PubMed ID: 8786532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity.
    Walenga JM; Bara L; Petitou M; Samama M; Fareed J; Choay J
    Thromb Res; 1988 Jul; 51(1):23-33. PubMed ID: 3166242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin.
    Buchanan MR; Boneu B; Ofosu F; Hirsh J
    Blood; 1985 Jan; 65(1):198-201. PubMed ID: 3965047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).
    Petitou M; Duchaussoy P; Jaurand G; Gourvenec F; Lederman I; Strassel JM; Bârzu T; Crépon B; Hérault JP; Lormeau JC; Bernat A; Herbert JM
    J Med Chem; 1997 May; 40(11):1600-7. PubMed ID: 9171870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.
    Walenga JM; Petitou M; Lormeau JC; Samama M; Fareed J; Choay J
    Thromb Res; 1987 Apr; 46(2):187-98. PubMed ID: 3603420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
    Berry CN; Girard D; Lochot S; Lecoffre C
    Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic study of three synthetic AT-binding pentasaccharides in various animal species-extrapolation to humans.
    Hérault JP; Donat F; Bàrzu T; Crépon B; Bernat A; Lormeau JC; Herbert JM
    Blood Coagul Fibrinolysis; 1997 Apr; 8(3):161-7. PubMed ID: 9167016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antithrombotic efficacy of the GP IIb/IIIa antagonist SR121787 is potentiated by antithrombin-dependent factor Xa inhibition without an increase in the bleeding risk in the rabbit.
    Bernat A; Savi P; Lale A; Hoffmann P; Herbert JM
    J Cardiovasc Pharmacol; 1999 Apr; 33(4):573-9. PubMed ID: 10218727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis.
    Fioravanti C; Burkholder D; Francis B; Siegl PK; Gibson RE
    Thromb Res; 1993 Aug; 71(4):317-24. PubMed ID: 8236160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.